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Abstract

The purpose of this study is to explore the associations between polypharmacy and multimorbidity using
conventional and novel measures of polypharmacy. In this cross-sectional study, data on fee-for-service (FFS)
Medicaid enrollees with at least 1 chronic condition and aged 18–64 years (N = 38,329) were derived from the
2010 Medicaid Analytic eXtract (MAX) files of Maryland and West Virginia. Polypharmacy, by the authors’
novel definition, was determined as simultaneous use of ‡5 drugs for a consecutive period of 60 days. Multimorbidity was defined as having ‡2 chronic conditions based on the US Department of Health and Human
Services framework. The association between multimorbidity and polypharmacy was examined with chi-square
tests and logistic regression. Polypharmacy prevalence was estimated at 50.9% using the novel definition, as
compared to 16.7% and 64.9% for the 2 commonly used conventional measures, respectively. For all 3
definitions, individuals with multimorbidity were more likely to have polypharmacy than those without multimorbidity (P < 0.001). The authors also consistently found, using all definitions, that those who were older,
female, white, and eligible for Medicaid because of cash assistance were more likely to have polypharmacy (all
P < 0.001). Polypharmacy was highly prevalent and significantly associated with multimorbidity among
Medicaid FFS enrollees irrespective of the definitions used. The new measure may provide a more comprehensive and accurate estimation of polypharmacy than the conventional measures. These findings suggest the
need for a paradigm shift from disease-specific care to patient-centered collaborative care to manage patients
with multimorbidity and polypharmacy.
Keywords: Medicaid, polypharmacy, multimorbidity, multiple chronic conditions

Introduction

P

olypharmacy, referred to as the concurrent use of
multiple drugs, is an economic and public health issue
that is related to the quality and efficiency of health care.1
Polypharmacy often needs to be considered in the context
of multimorbidity, defined as the presence of ‡2 chronic
diseases,2 to justify its appropriateness.3 A patient with
multimorbidity very likely will receive multiple drugs from
multiple prescribers. Current evidence-based clinical practice primarily follows single disease-specific treatment and
prevention guidelines; however, this kind of practice paradigm may sometimes be detrimental and impractical for patients with multimorbidity.4,5 For example, in Boyd et al, if

all recommendations from the clinical practice guideline of
each disease were followed, a hypothetical 79-year-old patient with diabetes, hypertension, osteoporosis, osteoarthritis,
and chronic obstructive pulmonary disease (COPD) would
take 12 separate drugs at 5 times comprising almost 19 doses
a day, which also raises issues such as drug-drug interactions
and even contraindications.6 Therefore, though not all polypharmacy is inappropriate in the clinical context, often it still
is associated with negative consequences, including harmful
drug-drug interactions, hospital readmissions, and frequent
emergency department visits.7,8
Historically, these issues were studied mostly in the elderly;
recent studies suggest that multimorbidity and polypharmacy
may extend to a more general population. According to
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Ornstein et al,9 the prevalence of multimorbidity in the United
States is about 40% by age 50, and increases to 66% in the group
who are ages 55–64. A geographic information system analysis
of the prevalence of polypharmacy in Italy found that geographical differences were better explained by the distribution of the
epidemiology of diseases and patients’ health than by age.10
However, very few studies have examined this relationship in the
non-elderly population. In addition, the Medicaid population,
who are generally non-elderly with limited income and resources,
may be more vulnerable to certain negative health outcomes
including multimorbidity,11 which may lead to a high prevalence
of polypharmacy as well. Exploring polypharmacy prevalence
and patterns in different chronic conditions or combinations may
suggest targets for future efforts to prevent negative consequences associated with polypharmacy and inappropriate use of
medications in this population.
On the other hand, previous literature has not established
a standard definition or measurement of polypharmacy,
which leads to heterogeneous measurements of polypharmacy prevalence and outcomes across studies. In particular,
there is no comprehensive operational definition of polypharmacy for research using administrative claims data,
a method that is cost-effective and reflective of real-world
clinical practice. An Italian study assessing geographic differences in polypharmacy defined polypharmacy as ‘‘the administration of five or more drugs during 1 month for at least 6
months (consecutive or not) in a year.’’10 Moriarty et al’s study
on polypharmacy trends in Ireland defined polypharmacy as ‡5
regular medications in 1 year.5 These definitions used in claims
data studies have taken into consideration the number of drugs
used and duration of use, but another important aspect of
polypharmacy is missing — the simultaneous use of drugs.
Simultaneous polypharmacy, determined as the sum of drugs
used concurrently on any given day, can provide comprehensive information on patients’ medication use and detect transient changes in use, although more information and
computation may be required to measure it.1,12
Therefore, the present study integrated the simultaneous
polypharmacy approach established by Fincke et al that
considers the number of drugs and duration of medication
use to develop a novel operational definition for polypharmacy,12 which can be applied when using pharmacy
claims data. The aim is to evaluate the association between
multimorbidity and polypharmacy by both the novel and
commonly-used conventional definitions of polypharmacy,
using the West Virginia (WV) and Maryland (MD) Medicaid fee-for-service (FFS) claims data.
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Department of Health and Human Services (DHHS) framework,13 which included hypertension, congestive heart failure
(CHF), coronary artery disease, cardiac arrhythmias, hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney
disease (CKD), COPD, dementia, depression, diabetes, hepatitis, HIV, osteoporosis, schizophrenia, and substance abuse
disorders. Figure 1 shows the flowchart for obtaining the final
study population. The study was approved by West Virginia
University’s Institutional Review Board (protocol number:
1511901393).
Measures
Dependent variable: polypharmacy. Definition 1 (New
definition): polypharmacy was defined as the simultaneous
use of ‡5 different drug classes for a 60-day consecutive
period. First, the research team identified drugs using the
national drug codes and categorized them into therapeutic
drug classes. Second, to measure the simultaneous use of
drugs, the team extracted pharmacy claims, including information on prescription fill date and days of supply, and
established separate data sets of pharmacy claims for each
drug class. For each drug class data set, the team created a
patient-level matrix marking all dates with the particular
drug class taken. Then for each individual, all matrixes were
merged together to obtain a final matrix that described the
daily use of drug classes in the follow-up period. Third, to
determine polypharmacy, the team marked the dates with
‡5 different drug classes for each patient on the final matrix.
Then a 60-day consecutive period was chosen to indicate
continuous use of drugs. In light of potential issues related
to patient nonadherence to medications,12 the research team

Methods
Study design, study population, and data source

The research team conducted a cross-sectional study in
2010 using Medicaid Analytic eXtract (MAX) files. The data
source was 2010 MAX data system for WV and MD. The
team used person summary files to obtain demographic and
enrollment data, inpatient files to identify hospital claims,
prescription drug files for pharmacy claims, and other services files to identify the diagnosis codes from outpatient
visits and other services. The team included adults who were
alive and aged 18 to 64 in 2010, continuously enrolled in WV
or MD Medicaid’s FFS program, not eligible for Medicare,
and with at least 1 of the chronic conditions based on the US

FIG. 1.

Flowchart for obtaining the final study population.

POLYPHARMACY AND MULTIMORBIDITY IN MEDICAID

125

also allowed a gap in the consecutive period window. Given
the widely-used cutoff point of 0.8 in medication adherence
research using claims data, a 12-day gap was allowed in the
consecutive use period. Therefore, polypharmacy was defined as an instance in which an individual took drugs from
‡5 different drug classes per day for at least 60 days out of
72 consecutive days in 2010.
The research team also applied the following 2 commonlyused, conventional definitions of polypharmacy in the previous literature:
Definition 2 (conventional definition): polypharmacy was
referred to the average number of drug classes that was 1
standard deviation above the mean in a 90-day period.8,14,15
Definition 3 (conventional definition): polypharmacy was
determined as >5 different drug classes used in an arbitrary
90-day period.16

nonwhite), and Medicaid pathway to eligibility (cash assistance, other).

Independent variable: multimorbidity. Multimorbidity
was defined as the coexistence of ‡2 chronic conditions.
These were identified in the medical claims using the International Classification of Diseases, Ninth Revision, Clinical
Modification. The selection of chronic conditions was based
on the DHHS framework.13
Covariates. Other covariates included age group (18–
34, 35–44, 45–54, 55–64), sex (female, male), race (white,

Statistical analyses

The research team presents descriptive statistics of total
Medicaid enrollees and patients with polypharmacy by each
definition with frequencies and percentages. The team compared the most prevalent combinations of comorbidities as well
as polypharmacy prevalence by the novel and 2 conventional
definitions. The bivariate association between polypharmacy
and multimorbidity was assessed by chi-square tests. Multivariate logistic regression also was used to further examine the
relationship between polypharmacy and multimorbidity after
adjusting for other covariates. Analyses were conducted using
SAS 9.4 (SAS Institute Inc., Cary, NC) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results

This study included a total of 38,329 Medicaid FFS enrollees, with 90.4% from WV and 9.6% from MD (Table 1).
Most of the study subjects were female, white, and middleaged (45–64 years old, 65.3%). Approximately 65% of the
Medicaid population in this study had multimorbidity with
the presence of ‡2 chronic conditions. The majority of patients with polypharmacy, regardless of definition, were

Table 1. Descriptive Statistics of 2010 Fee-for-Service Medicaid Enrollees
in West Virginia and Maryland (n = 38,329)

Variables
Sex
Male
Female
Age group, years
18–34
35–44
45–54
55–64
Race
White
Nonwhite
State
West Virginia
Maryland
Medicaid pathway to eligibility
Cash eligibility
Others
No. of chronic conditionsb
1 chronic condition
2 chronic conditions
3 chronic conditions
‡4 chronic conditions

Polypharmacy patients, n (%)a

All eligible
patients, n (%)

Definition 1

Definition 2

Definition 3

38,329 (100)

19,500 (50.9)

6404 (16.7)

24,882 (64.9)

15,636 (40.8)
22,693 (59.2)

6937 (35.6)
12,563 (64.4)

1568 (24.5)
4836 (75.5)

8670 (34.8)
16,212 (65.2)

6358
6945
13,121
11,905

(16.6)
(18.1)
(34.2)
(31.1)

1442
3012
7335
7711

(7.4)
(15.5)
(37.6)
(39.5)

273
859
2425
2847

(4.3)
(13.4)
(37.9)
(44.5)

2533
4219
9193
8937

(10.2)
(17.0)
(37.0)
(35.9)

34,706 (90.6)
3623 (9.5)

18,054 (92.6)
1446 (7.4)

6049 (94.5)
355 (5.5)

22,971 (92.3)
1911 (7.7)

34,662 (90.4)
3667 (9.6)

18,078 (92.7)
1422 (7.3)

6072 (94.8)
332 (5.2)

23,037 (92.6)
1845 (7.4)

31,451 (82.1)
6878 (17.9)

16,599 (85.1)
2901 (14.9)

5659 (88.4)
745 (11.6)

20,882 (83.9)
4000 (16.1)

13,624
9891
6705
8109

(35.5)
(25.8)
(17.5)
(21.2)

3574
4979
4445
6502

(18.3)
(25.5)
(22.8)
(33.3)

493
1046
1390
3475

(7.7)
(16.3)
(21.7)
(54.3)

5392
6577
5463
7450

(21.7)
(26.4)
(22.0)
(29.9)

a
Definition-1 (new polypharmacy definition) is the simultaneous use of ‡5 different drug classes for a 60-day consecutive period;
Definition-2 is the average number of drug classes that was 1 standard deviation above the mean in a 90-day period; Definition-3 is >5
different drug classes used in an arbitrary 90-day period.
b
Chronic conditions included in the list were: hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias,
hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, dementia, depression,
diabetes, hepatitis, HIV, osteoporosis, schizophrenia, and substance abuse disorders.

1865 (29.1)

1906 (29.8)

3452 (17.7)

3832 (19.7)

3957 (20.3)

4406 (11.5)

4848 (12.7)

5263 (13.7)

Hypertension +
hyperlipidemia
Hypertension +
diabetes
Hypertension +
depression
Diabetes +
hyperlipidemia
Hypertension + COPD
5

4

3

2

1

Most current definitions of polypharmacy used in research with claims data are limited because they do not

Rank

Discussion

Definition-1 (new polypharmacy definition) is the simultaneous use of ‡5 different drug classes for a 60-day consecutive period; Definition-2 is the average number of drug classes that was 1
standard deviation above the mean in a 90-day period; Definition-3 is >5 different drug classes used in an arbitrary 90-day period.
COPD, chronic obstructive pulmonary disease.

3988 (16.0)

4322 (17.4)

4662 (18.7)
1910 (29.8)

2345 (36.6)
5598 (28.7)

Definition 3
n (%)
Definition 2
n (%)

Definition 1

n (%)

Polypharmacy

female, older than 45 years of age, with cash assistance,
from WV, and had multimorbidity.
In the study Medicaid population, the prevalence of polypharmacy identified by definition-1 (new definition) was
50.9%; prevalence rates determined by conventional
definition-2 and definition-3 were 16.7% and 64.9%, respectively (Table 1). The new definition identified 99.2% of
polypharmacy determined by commonly-used definition-2;
approximately 58.8% of non-polypharmacy cases in
definition-2 also were negative cases according to the new
definition (Table 2). Similarly, when the new definition and
conventional definition-3 were compared, the 2 statistics were
76.6% and 96.6%, respectively. These indicated fair to good
agreement between the novel and conventional measures.
The most prevalent comorbidity combinations (2 coexisting conditions) in this population were hypertension and
hyperlipidemia (19.4%), following by hypertension and diabetes, and hypertension and depression (Table 3). They
also were the most prevalent combinations among patients
with polypharmacy, regardless of the definition used (Table 3). The comorbidity combinations (2 coexisting conditions) with the highest polypharmacy rate were CHF with
osteoporosis for the new definition, CKD with COPD for
definition-2, and CKD with osteoporosis for the definition-3
(data not shown). Throughout all definitions, patients with
comorbidity combinations such as CKD with osteoporosis,
CHF with osteoporosis, CKD with arthritis, and CHF with
arthritis had particularly high prevalence of polypharmacy.
Univariate analysis results show that individuals with a
greater number of chronic conditions had higher rates of polypharmacy under all 3 definitions (all P < 0.001) (data not shown).
The significantly positive relationship between polypharmacy
and multimorbidity also was demonstrated in the multivariable
logistic models (Table 4). The likelihood of polypharmacy, regardless of definition, increased with the number of chronic
conditions (all P < 0.001). The research team also consistently
found, using all definitions, that those who were older, female,
white, and eligible for Medicaid because of cash assistance were
more likely to have polypharmacy (all P < 0.001).

Total

Definition-1 (new polypharmacy definition) is the simultaneous
use of ‡5 different drug classes for a 60-day consecutive period;
Definition-2 is the average number of drug classes that was 1
standard deviation above the mean in a 90-day period; Definition-3
is >5 different drug classes used in an arbitrary 90-day period.

Most prevalent dual comorbidities among the total enrollees and polypharmacy patients

<0.0001

7210 (18.8)

5834 (23.4)
12,995 (96.6)

Hypertension +
diabetes
Hypertension +
hyperlipidemia
Hypertension +
depression
Diabetes +
hyperlipidemia
Hypertension +
COPD

19,048 (76.6)
452 (3.4)

<0.0001

2746 (42.9)

49 (0.8)
18780 (58.8)

Hypertension +
diabetes
Hypertension +
hyperlipidemia
Hypertension +
COPD
Hypertension +
depression
Diabetes +
hyperlipidemia

6355 (99.2)
13145 (41.2)

P

5664 (29.1)

No, n (%)

Table 3. Most Prevalent Dual Comorbidities and the Dual Comorbidities with Top Polypharmacy Rate

Definition 2
Yes
No
Definition 3
Yes
No

Yes, n (%)

Hypertension +
diabetes
Hypertension +
hyperlipidemia
Hypertension +
depression
Diabetes +
hyperlipidemia
Hypertension + COPD

Definition 1 (novel definition)

7453 (19.4)

n (%)

Table 2. Comparisons of Polypharmacy Prevalence
by Different Polypharmacy Definitions (n = 38,329)

6402 (25.7)
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6407 (25.8)
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Table 4. Multivariate Logistic Regression of the Association Between Polypharmacy
and Multimorbidity Among Medicaid Enrollees (n = 38,329)
Polypharmacy

Multimorbidity
2 conditions vs. 1
3 conditions vs. 1
‡4 conditions vs. 1
Age group
35–44 vs. 18–34
45–54 vs. 18–34
55–64 vs. 18–34
Sex (female vs. male)
Race (White vs. Nonwhite)
Medicaid pathway-to-eligibility
(cash eligibility vs. others)

Definition 1

Definition 2

Definition 3

AOR (95% CI)

AOR (95% CI)

AOR (95% CI)

2.47 (2.33–2.61)
4.59 (4.30–4.90)
8.88 (8.28–9.51)

2.73 (2.44–3.05)
5.84 (5.24–6.52)
16.49 (14.87–18.29)

2.78 (2.63–2.94)
6.07 (5.64–6.53)
14.93 (13.65–16.34)

1.93
2.70
3.31
1.41
1.80
1.40

(1.78–2.10)
(2.51–2.90)
(3.07–3.58)
(1.35–1.48)
(1.66–1.95)
(1.32–1.49)

1.92
2.40
2.69
2.29
2.13
1.64

(1.65–2.23)
(2.09–2.75)
(2.35–3.09)
(2.14–2.45)
(1.88–2.41)
(1.51–1.81)

1.68
2.07
2.12
1.96
1.97
1.30

(1.55–1.81)
(1.93–2.22)
(1.97–2.28)
(1.87–2.06)
(1.81–2.14)
(1.22–1.38)

Definition-1 (new definition) is the simultaneous use of ‡5 different drug classes for a 60-day consecutive period; Definition-2 is the
average number of drug classes that was 1 standard deviation above the mean in a 90-day period; Definition-3 is >5 different drug classes
used in an arbitrary 90-day period.
AOR, adjusted odds ratio; CI, confidence interval.

account for daily use of multiple medications. By incorporating 3 important components used to define polypharmacy
–number of drugs, simultaneous use of drugs on a daily
base, and duration of use – the research team developed a
novel measure to assess polypharmacy using Medicaid
claims data. Using this definition, the team found that
polypharmacy was highly prevalent (50.9%) in WV and MD
Medicaid populations who have at least 1 chronic condition,
and was significantly associated with multimorbidity, implying considerable burdens of polypharmacy and multimorbidity among the Medicaid population in these 2 states.
The new and old measures were broadly concordant. The
new measure identified more than 99% or 76.6% of polypharmacy cases defined by 2 conventional measures; approximately 59% or 97% of the non-polypharmacy patients
by the 2 measures also were negative cases as determined by
the new definition. This suggests good agreement between
the novel and conventional measures. Additionally, the positive relationship between polypharmacy and multimorbidity
was corroborated by the univariate and multivariate analyses
using all measures.
Nevertheless, compared to the conventional measures, the
new measure provides a clearer and more comprehensive
view of polypharmacy. Incorporating daily drug use and
other important components into the new definition provides
a more accurate estimation of polypharmacy burden and can
capture transient and longitudinal changes, which can help
us to better understand the antecedents and consequences
associated with polypharmacy issues. The new measure also
is flexible and feasible to use with claims data, as it can be
applied to different levels of drug classes, number of drug
classes, and assessment periods.
The analyses showed that polypharmacy was not only
positively associated with number of chronic conditions in
the Medicaid population, but also varied among different
disease combinations. It was found that patients with CKD
and musculoskeletal conditions as well as CHF and mus-

culoskeletal conditions had considerable polypharmacy
burdens. First, patients with CKD with or without other
conditions may be particularly at risk of polypharmacy.
Multimorbidity and multiple drug use may contribute to the
physiological decline in renal function.17 As renal function
deteriorates, it is necessary to add more drugs to manage the
complications or comorbidities including cardiometabolic
conditions, musculoskeletal conditions, and anemia,17,18
which further complicate medication regimens.19,20 For patients with CHF, multimorbidity also is exceedingly common
across all ages, which leads to overwhelmingly significant
burdens from the diseases and treatments with high complexity.21,22 It has even been suggested that nonpharmacological treatments be prioritized and polypharmacy reduced
to alleviate the treatment burden in patients with CHF.22 In
terms of musculoskeletal conditions such as arthritis, the
management of the disease itself demands multiple drugs
such as analgesics, anti-inflammatory drugs, corticosteroids,
or biologics, as well as other drugs to treat comorbidities.
Therefore, the literature has often documented a high prevalence of polypharmacy in patients with CKD and musculoskeletal conditions.23–26 Nevertheless, future research may
be warranted to further examine the differences in polypharmacy and inappropriate medication use across various
types of chronic conditions or combinations among different
populations.
The present study had several limitations. First, the crosssectional study design limits the ability to establish causality
in the findings. Second, the main therapeutic drug classes
were used to measure polypharmacy instead of the single
active ingredient; therefore, this study is only able to estimate
polypharmacy from different drug classes but not within
the drug classes. This may lead to underestimation of polypharmacy rates, but the measurement may be more feasible
to implement with claims data given the tremendous amount
of data and computation challenges. Third, measurement of
polypharmacy did not fully address early refill issues. But
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allowing for a 12-day gap in the calculation might mitigate
this potential issue to some extent. Fourth, the data source had
limited ability to capture patients’ actual medication-taking
behavior, over-the-counter medications, accurate drug indications, and disease severity, which may influence either the
accuracy of estimation or the differentiation between appropriate and inappropriate polypharmacy. Fifth, only 19 chronic
conditions were included in the analyses, which also may
result in the underestimation of multimorbidity in the study
population. Lastly, the population was adult Medicaid FFS
program enrollees in WV and MD in 2010; thus, the findings
may not be generalizable to populations in other regions or
with other health care plans, or may not reflect the most updated situation in the study population.
Despite the limitations, the study findings have implications
for researchers, clinicians, and policy makers. This study found
that even in the Medicaid population, a majority of whom are
not elderly, multimorbidity and polypharmacy are prevalent
and highly correlated. There is limited clinical evidence or
guidelines for multimorbidity,4 and most clinical trials exclude
patients with multimorbidity and polypharmacy.27 Furthermore, physicians tend to adhere to single-disease guidelines
when prescribing medications as recommended.28,29 Therefore, there is a need for more evidence on managing patients
with multimorbidity and polypharmacy, which can lead to
more comprehensive guidelines for these high-risk patients.
Moreover, in a system such as FFS, which lacks financial incentives for care coordination, a patient with multimorbidity
very likely will receive multiple medications from multiple
prescribers without adequate review or monitoring of medications.16 Interventions or policies directed at reducing inappropriate polypharmacy must consider fostering collaboration
among different health care professionals to review and monitor all medications taken to ensure the appropriateness and
safety of drugs with the support of a sustainable financial
model. The new definition of polypharmacy presented here
may provide a feasible and cost-effective way to use claims
data to identify targeted populations such as those with polypharmacy or multimorbidity, and those using high-risk drugs or
drug combinations, ultimately achieving the goal of reducing
preventable medication-related harm to patients as well as
associated excessive costs.
Conclusion

In this study, polypharmacy was highly prevalent and
significantly associated with multimorbidity among Medicaid
FFS enrollees, irrespective of the definition used. The new
measure developed to be applied to claims data may provide a
more comprehensive and accurate estimation of polypharmacy compared to conventional measures. Patients with
certain chronic conditions or combinations, such as a chronic
kidney condition or heart failure with musculoskeletal conditions, may be at higher risk of polypharmacy. This study’s
findings suggest the need for a paradigm shift from diseasespecific care to patient-centered collaborative care to manage
patients with multimorbidity and polypharmacy.
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